±Û·çÄ«°ï À¯»çÆéƼµå 1(GLP-1) ½ÃÀå ºÐ¼®°ú ¿¹Ãø : À¯Çüº°, Á¦Ç°º°, ¼­ºñ½ºº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Àü°³º°, µð¹ÙÀ̽ºº°, ÇÁ·Î¼¼½ºº°
GLP 1 Market Analysis and Forecast to 2034: Type, Product, Services, Technology, Application, End User, Deployment, Device, Process
»óǰÄÚµå : 1813533
¸®¼­Ä¡»ç : Global Insight Services
¹ßÇàÀÏ : 2025³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 312 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,750 £Ü 6,731,000
Single User License help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇϸç, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 5,750 £Ü 8,148,000
Site License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(±¹°¡)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,750 £Ü 9,565,000
Enterprise License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ Àü ¼¼°è ¸ðµçºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

GLP-1 ½ÃÀåÀº 2024³â 937¾ï ´Þ·¯¿¡¼­ 2034³â¿¡´Â 2,218¾ï ´Þ·¯·Î È®´ëµÇ¾î CAGR ¾à 9%¸¦ ´Þ¼ºÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. GLP-1 ½ÃÀåÀº ±Û·çÄ«°ï À¯»ç ÆéƼµå 1 ¼ö¿ëü ÀÛ¿ëÁ¦¸¦ Æ÷ÇÔÇϸç, ÁÖ·Î 2Çü ´ç´¢º´°ú ºñ¸¸ÀÇ °ü¸®¿¡ »ç¿ëµÇ´Â ¾àÁ¦±ºÀÔ´Ï´Ù. ÀÌ ¾àÀº Àν¶¸° ºÐºñ¸¦ ÃËÁøÇÏ°í ½Ä¿åÀ» ¾ïÁ¦Çϸç À§ ¹èÃâÀ» Áö¿¬½Ãŵ´Ï´Ù. ´ç´¢º´ ÀÌȯÀ²°ú ºñ¸¸·üÀÇ »ó½ÂÀÌ ¼ö¿ä¸¦ ÀÚ±ØÇϸç, Çõ½ÅÀûÀÎ ¾àÁ¦´Â ¼­¹æÇü Á¦Á¦¿Í º´¿ë ¿ä¹ý¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. GLP-1 ½ÃÀå¿¡¼­´Â ÇコÄɾ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö¸é¼­ À¯¸®ÇÑ È¯±Þ Á¤Ã¥¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.

GLP-1 ½ÃÀåÀº ´ç´¢º´°ú ºñ¸¸ÀÇ À¯º´·ü »ó½Â¿¡ ÈûÀÔ¾î °­·ÂÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. GLP-1 ½ÃÀåÀº ´ç´¢º´°ú ºñ¸¸ÀÇ À¯º´·ü Áõ°¡¿¡ ÈûÀÔ¾î źźÇÑ ¼ºÀåÀ» º¸¿©ÁÝ´Ï´Ù. ÀÌ ½ÃÀå¿¡¼­ ¼¼¸¶±Û·çƼµå¿Í ¸®¶ó±Û·çƼµå´Â È¿´É°ú ȯÀÚ ÄÄÇöóÀ̾𽺷Π½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àº Ç÷´çÀ» È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö Àֱ⠶§¹®¿¡ Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù. µÎ ¹øÂ°·Î ³ôÀº ¼º°ú¸¦ °ÅµÎ°í ÀÖ´Â ÇÏÀ§ ºÎ¹®Àº º´¿ë ¿ä¹ýÀ¸·Î, º¹¼öÀÇ °æ·Î¸¦ Ç¥ÀûÀ¸·Î ÇÔÀ¸·Î½á Ä¡·á È¿°ú¸¦ ³ôÀÏ ¼ö ÀÖ¾î ±â¼¼¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ¾à¸®ÇÐÀû Áøº¸ ¿Ü¿¡µµ Àü´Þ ½Ã½ºÅÛ ºÐ¾ß¿¡¼­µµ Å« ±â¼ú Çõ½ÅÀ» º¼ ¼ö ÀÖ½À´Ï´Ù. ÁÖ»ç¿ë Ææ°ú ÀÚµ¿ ÁÖ»ç±â°¡ ÃÖ÷´ÜÀ» ´Þ¸®°í ÀÖÀ¸¸ç, Åõ¿©ÀÇ Æí¸®¼º°ú Á¤È®¼ºÀ» Á¦°øÇÕ´Ï´Ù. ¹Ý¸é¿¡, °æ±¸ GLP-1 Á¦ÇüÀº ºñħ½ÀÀûÀÎ ¼±Åÿ¡ ´ëÇÑ È¯ÀÚÀÇ ¼±È£µµ¿¡ ÀÇÇØ À¯¸ÁÇÑ ÇÏÀ§ ºÎ¹®À¸·Î ºÎ»óÇÕ´Ï´Ù. ¹ÙÀÌ¿À °¡¿ë¼º Çâ»ó°ú ÀÛ¿ë ½Ã°£ ¿¬Àå¿¡ ÃÊÁ¡À» ¸ÂÃá R&D ÅõÀÚ°¡ Ȱ¹ßÇØÁö°í ÀÖÀ¸¸ç, Ä¡·á ¿µ¿ªÀÇ È®´ë¿Í »õ·Î¿î ¼ºÀå ±âȸÀÇ È¹µæÀÌ ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­
À¯Çü ÆéƼµåÇü GLP-1 È¿´ÉÁ¦, ºñÆéƼµåÇü GLP-1 È¿´ÉÁ¦
Á¦Ç° ÁÖ»ç¿ë GLP-1 È¿´ÉÁ¦, °æ±¸ GLP-1 È¿´ÉÁ¦
»ç¾÷³»¿ë ÀÓ»ó½ÃÇè, ±ÔÁ¦ ÄÁ¼³ÆÃ, ¾à¹°°¨½Ã
±â¼ú ÀçÁ¶ÇÕ DNA ±â¼ú, È­ÇÐ ÇÕ¼º
¿ëµµ 2Çü ´ç´¢º´, ºñ¸¸ °ü¸®, ½ÉÇ÷°ü ¿ëµµ
ÃÖÁ¾ »ç¿ëÀÚ º´¿ø, Ŭ¸®´Ð, ¿¬±¸±â°ü, Á¦¾àȸ»ç
¹èÆ÷ ÀÎÇϿ콺, ¾Æ¿ô¼Ò½Ì
ÀåÄ¡ Àν¶¸° Ææ, ÁÖ»ç±â, ÀÚµ¿ ÁÖ»ç±â
ÇÁ·Î¼¼½º ½Å¾à °³¹ß, ÀǾàǰ °³¹ß, Á¦Á¶

½ÃÀå ÇöȲ

GLP-1 ½ÃÀåÀº Àü·«ÀûÀÎ °¡°Ý ¼³Á¤°ú Çõ½ÅÀûÀÎ Á¦Ç°ÀÇ Ãâ½Ã¸¦ ÅëÇØ ÆÐ±ÇÀ» ´ÙÅõ´Â ´Ù¾çÇÑ ±â¾÷À» Ư¡À¸·Î ÇÕ´Ï´Ù. GLP-1 ½ÃÀåÀº »õ·Î¿î Ä¡·áÁ¦¿Í °³¼±µÈ Á¦ÇüÀÇ µµÀÔÀ¸·Î ½ÃÀå Á¡À¯À²ÀÇ ¿ªµ¿ÀûÀÎ º¯µ¿¿¡ ÀÇÇØ Á¤Àǵ˴ϴÙ. °¡°Ý Àü·«Àº ¸Å¿ì Áß¿äÇÏ¸ç °¢ ȸ»ç´Â °æÀï·ÂÀÖ´Â °¡°Ý ¼³Á¤À¸·Î ½ÃÀå¿¡¼­ÀÇ Á¸Àç°¨À» ³ôÀÔ´Ï´Ù. ¼ö¿ä¿¡ ´ëÇÑ ´ëÀÀ°ú ȯÀÚ¿¡ ´ëÇÑ Ä¡·á ¿É¼ÇÀÇ È®´ë¶ó´Â ¾÷°èÀÇ Çå½ÅÀ» ¹Ý¿µÇÏ¿©, ½ÅÁ¦Ç°ÀÇ Ãâ½Ã´Â ºó¹øÈ÷ ÇàÇØÁö°í ÀÖ½À´Ï´Ù. GLP-1 ½ÃÀå¿¡¼­ÀÇ °æÀïÀº Ä¡¿­Çϰí, ÁÖ¿ä Á¦¾à±â¾÷Àº °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ¿µÇâµµ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ¾ö°ÝÇÑ ÁöħÀÌ Á¦Ç° °³¹ß°ú ½ÃÀå °³Ã´ Àü·«À» Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀå¿¡¼­´Â Çõ½Å °¡¼ÓÈ­¿Í ½ÃÀå ÁøÀÔ È®´ë¸¦ ¸ñÇ¥·Î ÇÑ Àü·«Àû ÆÄÆ®³Ê½Ê°ú Á¦ÈÞ°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì¿Í À¯·´ÀÇ ±ÔÁ¦ ƲÀº ƯÈ÷ Å« ¿µÇâÀ» ¹ÌÄ¡¸ç ±ÔÁ¤ Áؼö ±âÁØÀ» ±ÔÁ¤ÇÏ°í ½ÃÀå ¿ªÇп¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. °æÀï ±¸µµ´Â »õ·Î¿î °üÁ¡°ú Çõ½ÅÀûÀÎ ±â¼úÀ» Á¦°øÇÏ´Â ½ÅÈï ±â¾÷¿¡ ÀÇÇØ ´õ¿í º¹ÀâÇØÁö°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä µ¿Çâ°ú ÃËÁø ¿äÀÎ

GLP-1 ½ÃÀåÀº ¼¼°èÀûÀÎ ºñ¸¸°ú ´ç´¢º´ À¯º´·üÀÇ »ó½Â¿¡ ÈûÀÔ¾î °­·ÂÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦°¡ üÁß °ü¸®¿Í Ç÷´ç Á¶Àý¿¡ È¿°úÀûÀ̶ó´Â ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç´Â Çõ½ÅÀûÀ̰í È¿°úÀûÀÎ Á¦Á¦¸¦ µµÀÔÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä µ¿ÇâÀº ÁÖ»çÁ¦¸¦ ´ëüÇÏ´Â Æí¸®ÇÑ °æ±¸ GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ÀÇ °³¹ßÀ» Æ÷ÇÔÇÕ´Ï´Ù. ¶ÇÇÑ ÆÇ¸Å¸ÁÀ» °­È­ÇÏ°í ½ÃÀå µµ´Þ ¹üÀ§¸¦ È®´ëÇϱâ À§ÇÑ Àü·«Àû ÆÄÆ®³Ê½Ê°ú Á¦ÈÞµµ ³ªÅ¸³ª°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á ¹× È¯ÀÚ Áß½ÉÀÇ Á¢±Ù¹ýÀÌ º¸±ÞµÇ¾î °³º° ȯÀÚ ÇÁ·ÎÆÄÀÏ¿¡ ¸Â´Â Ä¡·á°¡ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÀÇ·áºñ Àý°¨¿¡ ´ëÇÑ °ü½É Áõ°¡´Â ´ç´¢º´ ÇÕº´Áõ°ú °ü·ÃµÈ Àå±âÀûÀÎ ÀÇ·áºñ Àý°¨ÀÇ °¡´É¼ºÀ¸·Î GLP-1 Ä¡·áÁ¦ÀÇ Ã¤¿ëÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ÀÎÇÁ¶ó °³¼±°ú °¡Ã³ºÐ ¼Òµæ Áõ°¡·Î ÷´Ü Ä¡·á¿¡ ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ´Â ½ÅÈï ½ÃÀå¿¡´Â ¸¹Àº ºñÁî´Ï½º ±âȸ°¡ Á¸ÀçÇÕ´Ï´Ù. GLP-1 ½ÃÀåÀº ±â¼ú Çõ½Å°ú Àü·«Àû ½ÃÀå Æ÷Áö¼Å´×¿¡ ÀÇÇØ »ó´çÇÑ È®´ë°¡ ¿¹»óµË´Ï´Ù.

¾ïÁ¦ ¿äÀΰú °úÁ¦

GLP-1 ½ÃÀåÀº ¸î °¡Áö Å« ¾ïÁ¦ ¿äÀΰú ¹®Á¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ¾ïÁ¦ ¿äÀÎ Áß Çϳª´Â GLP-1 Ä¡·áÁ¦ÀÇ °¡°ÝÀÌ ³ô±â ¶§¹®¿¡ ¸¹Àº ȯÀÚÀÇ Á¢±ÙÀ» Á¦ÇÑÇÏ°í ½ÃÀå ħÅõ¸¦ Á¦ÇÑÇÕ´Ï´Ù. °Ô´Ù°¡ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç°ú ±ä ½ÂÀÎ ÇÁ·Î¼¼½º´Â Å« Àå¾Ö¹°ÀÌ µÇ¾î ½ÅÁ¦Ç°°ú Çõ½ÅÀÇ µµÀÔÀ» ´ÊÃß°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á Á¾»çÀÚ¿Í È¯ÀÚÀÇ GLP-1 ¿ä¹ý¿¡ ´ëÇÑ Àνİú ÀÌÇØ°¡ Á¦ÇÑÀûÀÎ °Íµµ ÁÖ¸ñÇØ¾ß ÇÒ °úÁ¦ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ³·Àº ÀÎÁöµµ´Â ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ ÀÌ¿ë ºÎÁ·À¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. °Ô´Ù°¡, ½ÃÀåÀº »ýȰ ½À°ü¿¡ ´ëÇÑ °³ÀÔ°ú ´Ù¸¥ ¾à¹° ¿ä¹ý°ú °°Àº ´ëü Ä¡·á ¿É¼Ç°úÀÇ °æÀï¿¡ Á÷¸éÇϰí ÀÖÀ¸¸ç, ÀáÀçÀûÀΠȯÀÚ¸¦ GLP-1 Ä¡·á·ÎºÎÅÍ ¸Ö¸®ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î GLP-1 Ä¡·á¿Í °ü·ÃµÈ ºÎÀÛ¿ë °ü¸®ÀÇ º¹À⼺ÀÌ °úÁ¦°¡ µÇ¾ú½À´Ï´Ù. °Ç°­ °ü¸® Á¦°ø¾÷ü´Â ÀÌ·¯ÇÑ ºÎÀÛ¿ëÀ» ¸é¹ÐÈ÷ ¸ð´ÏÅ͸µÇÏ°í °ü¸®ÇØ¾ß Çϸç, Ä¡·á ¿ä¹ýÀ» º¹ÀâÇÏ°Ô Çϰí ȯÀÚÀÇ ¼øÀÀÀ» ¾ïÁ¦ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ±â¾÷

Ascendis Pharma, Hanmi Pharmaceuticals, Oramed Pharmaceuticals, Adocia, Chiasma, Amphastar Pharmaceuticals, Intarcia Therapeutics, Carmot Therapeutics, Diasome Pharmaceuticals, TheracosBio, Viking Therapeutics, Eiger BioPharmaceuticals, Pharma, Zydus Cadila

¸ñÂ÷

Á¦1Àå GLP-1 ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå¿¡ °üÇÑ Áß¿ä ÀλçÀÌÆ®

Á¦4Àå GLP-1 ½ÃÀå Àü¸Á

Á¦5Àå GLP-1 ½ÃÀå Àü·«

Á¦6Àå GLP-1 ½ÃÀå ±Ô¸ð

Á¦7Àå GLP-1 ½ÃÀå ±Ô¸ð : À¯Çüº°

Á¦8Àå GLP-1 ½ÃÀå : Á¦Ç°º°

Á¦9Àå GLP-1 ½ÃÀå : ¼­ºñ½ºº°

Á¦10Àå GLP-1 ½ÃÀå : ±â¼úº°

Á¦11Àå GLP-1 ½ÃÀå : ¿ëµµº°

Á¦12Àå GLP-1 ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦13Àå GLP-1 ½ÃÀå : Àü°³º°

Á¦14Àå GLP-1 ½ÃÀå : µð¹ÙÀ̽ºº°

Á¦15Àå GLP-1 ½ÃÀå : ÇÁ·Î¼¼½ºº°

Á¦16Àå GLP-1 ½ÃÀå : Áö¿ªº°

Á¦17Àå °æÀï ±¸µµ

Á¦18Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

CSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

GLP 1 Market is anticipated to expand from $93.7 billion in 2024 to $221.8 billion by 2034, growing at a CAGR of approximately 9%. The GLP-1 Market encompasses glucagon-like peptide-1 receptor agonists, a class of medications primarily used for managing type 2 diabetes and obesity. These agents enhance insulin secretion, suppress appetite, and slow gastric emptying. Rising diabetes prevalence and obesity rates fuel demand, with innovations focusing on extended-release formulations and combination therapies. The market is propelled by increasing healthcare awareness and favorable reimbursement policies.

The GLP-1 market is experiencing robust growth, propelled by the rising prevalence of diabetes and obesity. Within this market, the drug segment is the top performer, with semaglutide and liraglutide leading due to their efficacy and patient compliance. These drugs are favored for their ability to manage blood glucose levels effectively. The second highest performing sub-segment is the combination therapies, which are gaining momentum as they offer enhanced therapeutic benefits by targeting multiple pathways. In addition to pharmacological advancements, the delivery systems segment is witnessing significant innovation. Injectable pens and auto-injectors are at the forefront, offering convenience and precision in dosage administration. Meanwhile, oral GLP-1 formulations are emerging as a promising sub-segment, driven by patient preference for non-invasive options. Research and development investments are intensifying, focusing on improving bioavailability and extending the duration of action, thereby broadening the therapeutic landscape and unlocking new opportunities for growth.

Market Segmentation
TypePeptide-Based GLP-1 Agonists, Non-Peptide GLP-1 Agonists
ProductInjectable GLP-1 Agonists, Oral GLP-1 Agonists
ServicesClinical Trials, Regulatory Consulting, Pharmacovigilance
TechnologyRecombinant DNA Technology, Chemical Synthesis
ApplicationType 2 Diabetes, Obesity Management, Cardiovascular Applications
End UserHospitals, Clinics, Research Institutes, Pharmaceutical Companies
DeploymentIn-House, Outsourced
DeviceInsulin Pens, Syringes, Auto-Injectors
ProcessDrug Discovery, Drug Development, Manufacturing

Market Snapshot:

The GLP-1 market is characterized by a diverse array of market players, each vying for dominance through strategic pricing and innovative product launches. The landscape is defined by dynamic shifts in market share, influenced by the introduction of novel therapeutics and enhanced formulations. Pricing strategies are pivotal, with companies leveraging competitive pricing to capture greater market presence. New product launches are frequent, reflecting the industry's commitment to addressing unmet medical needs and expanding therapeutic options for patients. Competition within the GLP-1 market is intense, with leading pharmaceutical companies investing heavily in research and development to maintain their competitive edge. Regulatory influences play a crucial role, with stringent guidelines shaping product development and market entry strategies. The market is witnessing a surge in strategic partnerships and collaborations, aimed at accelerating innovation and expanding market reach. Regulatory frameworks in North America and Europe are particularly impactful, dictating compliance standards and influencing market dynamics. The competitive landscape is further complicated by emerging players, who bring fresh perspectives and novel technologies to the fore.

Geographical Overview:

The GLP-1 market is witnessing substantial growth across various regions, each showcasing unique dynamics. North America remains a dominant force, propelled by increasing prevalence of diabetes and obesity. The region benefits from robust healthcare infrastructure and heightened awareness of GLP-1 therapies. Europe follows closely, where strong healthcare systems and rising awareness of diabetes management are driving market expansion. In the Asia Pacific, the market is expanding swiftly due to a rising diabetic population and increased healthcare spending. Emerging economies like China and India are pivotal growth pockets, with significant investments in healthcare infrastructure. Latin America and the Middle East & Africa are also emerging markets. In Latin America, growing healthcare investments and improving access to diabetes treatments are notable. The Middle East & Africa are recognizing the importance of addressing lifestyle diseases, thus fostering demand for GLP-1 therapies. These regions offer lucrative opportunities for market players aiming to expand their global footprint.

Key Trends and Drivers:

The GLP-1 market is experiencing robust growth, propelled by rising obesity and diabetes prevalence worldwide. Increasing awareness of GLP-1 receptor agonists' efficacy in weight management and glycemic control is driving demand. Pharmaceutical companies are investing heavily in research and development to introduce innovative and more effective formulations. Key trends include the development of oral GLP-1 receptor agonists, offering a convenient alternative to injectable forms. The market is also witnessing strategic partnerships and collaborations to enhance distribution networks and expand market reach. Personalized medicine and patient-centric approaches are gaining traction, aligning treatments with individual patient profiles. The increasing focus on healthcare cost reduction is encouraging the adoption of GLP-1 therapies, given their potential to reduce long-term healthcare expenses associated with diabetes complications. Opportunities abound in emerging markets, where healthcare infrastructure improvements and rising disposable incomes are facilitating greater access to advanced therapies. The GLP-1 market is poised for significant expansion, driven by innovation and strategic market positioning.

Restraints and Challenges:

The GLP-1 market is encountering several significant restraints and challenges. One primary restraint is the high cost of GLP-1 therapies, which limits access for many patients and restricts market penetration. Additionally, stringent regulatory requirements and lengthy approval processes pose significant hurdles, delaying the introduction of new products and innovations. There is also a notable challenge in the form of limited awareness and understanding of GLP-1 therapies among healthcare professionals and patients. This lack of awareness can lead to underutilization of these therapies. Furthermore, the market faces competition from alternative treatment options, such as lifestyle interventions and other pharmacological therapies, which can divert potential patients away from GLP-1 treatments. Lastly, the complexity of managing side effects associated with GLP-1 therapies presents a challenge. Healthcare providers need to carefully monitor and manage these side effects, which can complicate treatment regimens and deter patient adherence.

Key Players:

Ascendis Pharma, Hanmi Pharmaceutical, Oramed Pharmaceuticals, Adocia, Chiasma, Amphastar Pharmaceuticals, Intarcia Therapeutics, Carmot Therapeutics, Diasome Pharmaceuticals, TheracosBio, Viking Therapeutics, Eiger BioPharmaceuticals, Protagonist Therapeutics, Scohia Pharma, Zydus Cadila

Research Scope:

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: GLP 1 Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: GLP 1 Market Outlook

5: GLP 1 Market Strategy

6: GLP 1 Market Size

7: GLP 1 Market, by Type

8: GLP 1 Market, by Product

9: GLP 1 Market, by Services

10: GLP 1 Market, by Technology

11: GLP 1 Market, by Application

12: GLP 1 Market, by End User

13: GLP 1 Market, by Deployment

14: GLP 1 Market, by Device

15: GLP 1 Market, by Process

16: GLP 1 Market, by Region

17: Competitive Landscape

18: Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â